Reviews/GLP-1 Receptor Agonists/Tirzepatide outperforms single GLP-1 receptor agonists
Metabolic · GLP1-MET-02 · v2
Two large head-to-head trials directly pitted tirzepatide against the GLP-1 drug semaglutide. In people with type 2 diabetes [1], tirzepatide lowered blood sugar more and produced greater weight loss; in people with obesity but no diabetes [7], it produced greater weight loss (20.2% versus 13.7%). A trial against another GLP-1 drug, dulaglutide [6], and several real-world and secondary datasets [8][9][15][17][20] point the same way. The weight-loss advantage is consistent and large, while the blood-sugar advantage is clear at the higher tirzepatide doses and small at the lowest dose [1]. The main caveats the panel noted are that both pivotal trials were open-label and that the semaglutide dose in the diabetes trial was capped below its maximum. On balance the evidence pointed firmly in one direction across different trial designs and patient groups.
A head-to-head phase 3 trial in type 2 diabetes [1] found tirzepatide noninferior and superior to semaglutide on HbA1c, with treatment differences of -0.15, -0.39 and -0.45 percentage points at 5, 10 and 15 mg, and greater weight reductions (-1.9, -3.6 and -5.5 kg). A head-to-head phase 3b trial in obesity [7] found weight change of -20.2% with tirzepatide versus -13.7% with semaglutide. A SURPASS-2 post hoc confirmed greater HbA1c and weight reductions across baseline quartiles [19], and a trial versus dulaglutide reported greater glucose control and weight loss [6]. Real-world and secondary datasets reproduce the direction: a matched EHR cohort showed a 12-month weight difference of -6.9% favouring tirzepatide [8], a secondary RCT analysis showed greater fat-mass loss [9], and other cohorts reported larger weight loss and HbA1c falls [15][17][20]. The contested point: The division is one of magnitude and strength, not direction: the glycaemic advantage is robust at tirzepatide 10 and 15 mg but marginal at 5 mg (-0.15 percentage points, 95% CI -0.28 to -0.03) [1], and the real-world weight gap is narrower than in trials, with a large non-responder fraction reported [20]. The open-label design of both pivotal trials [1][7] and the submaximal 1 mg semaglutide comparator in SURPASS-2 [1] are the panel's main reservations.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Both pivotal head-to-head RCTs ([1] SURPASS-2, [7] SURMOUNT-5) are open-label, not blinded, raising bias risk for weight- and adherence-sensitive endpoints.
In SURPASS-2 [1] semaglutide was capped at 1 mg (submaximal), and the glycaemic superiority at tirzepatide 5 mg was marginal (-0.15 pp, 95% CI -0.28 to -0.03); the glycaemic limb is not demonstrated against the highest-dose GLP-1 RA.
Where it remains uncertain. Both pivotal trials were open-label [1][7] and semaglutide was capped at 1 mg in SURPASS-2, where the 5 mg glycaemic advantage was marginal (-0.15 percentage points) [1].
Aleatory
Real-world data show substantial variability and a large non-responder fraction, with nearly 50% and 25% not reaching 10% and 5% weight-loss targets [20].
Epistemic
SURPASS-2 capped semaglutide at 1 mg, so the glycaemic advantage against the highest approved GLP-1 dose is not measured [1].
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Head-to-head RCT: tirzepatide superior weight loss vs semaglutide 1 mg in T2D.
“the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively.”
Panel auditInternal validity: high · scope of inference: Adults with type 2 diabetes, 40 weeks, tirzepatide vs semaglutide 1 mg.Key limitations: open-label · single semaglutide dose (1 mg, not 2 mg) · 40-week horizon
Superiority extends to a second GLP-1 RA comparator (dulaglutide).
“Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide.”
Panel auditInternal validity: medium · scope of inference: Type 2 diabetes, 26-week mechanistic sub-analysis, tirzepatide vs dulaglutide.Key limitations: post hoc analysis · focus on beta-cell/IR biomarkers · single dulaglutide dose
Second head-to-head RCT (obesity, max doses): tirzepatide superior weight loss vs semaglutide.
“The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).”
Panel auditInternal validity: high · scope of inference: Adults with obesity but without type 2 diabetes, 72 weeks, weight outcomes only.Key limitations: no diabetes / no glycaemic endpoint · open-label · weight-only claim coverage
3 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent head-to-head RCTs plus concordant real-world evidence carry both limbs of the claim, with open-label design and a submaximal semaglutide dose the only material caveats.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Superiority versus maximal-dose semaglutide. The glycaemic advantage is only shown against 1 mg semaglutide and is marginal at tirzepatide 5 mg [1]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A head-to-head trial using semaglutide 2.0 mg as the comparator on HbA1c and weight.
Open question: Does tirzepatide's glycaemic superiority hold against the maximal 2.0 mg dose of semaglutide? Why it is still open: SURPASS-2 capped semaglutide at 1 mg and the 5 mg tirzepatide HbA1c margin was only -0.15 percentage points [1].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19